TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03263819

Intervention type: DIAGNOSTIC_TEST
Intervention: Oral glucose tolerance test
Description: 75 grams of glucose

Intervention type: DIAGNOSTIC_TEST
Intervention: Oral glucose tolerance test
Description: 75 grams of glucose
Study: NCT04130919

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tilpisertib
Description: Tablets administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tilpisertib
Description: Tablets administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tilpisertib
Description: Tablets administered orally once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablets administered orally once daily
Study: NCT02351973

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrochlorthiazide
Description: HCTZ 25mg to 50mg All drugs will be provided in an acceptable container where the active agent is not identified on the drug label.~In Phase 1 (weeks 0-12) patients will have 1 tablet from each of 2 bottles. These will contain either a) HCTZ 12.5mg in both bottles; b) amiloride 5mg in both bottles; OR c) one bottle of each.~In Phase 2 (weeks13-24) patients will take 2 tablets from each of 2 bottles. These bottles will have the same contents as in Phase 1, except that the number of tablets will be twice as many.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amiloride
Description: Amiloride 10mg to 20mg All drugs will be provided in an acceptable container where the active agent is not identified on the drug label.~In Phase 1 (weeks 0-12) patients will have 1 tablet from each of 2 bottles. These will contain either a) HCTZ 12.5mg in both bottles; b) amiloride 5mg in both bottles; OR c) one bottle of each.~In Phase 2 (weeks13-24) patients will take 2 tablets from each of 2 bottles. These bottles will have the same contents as in Phase 1, except that the number of tablets will be twice as many.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrochlorthiazide and Amiloride
Description: HCTZ 12.5 to 25mg \& + Amiloride 5mg to 10mg All drugs will be provided in an acceptable container where the active agent is not identified on the drug label.~In Phase 1 (weeks 0-12) patients will have 1 tablet from each of 2 bottles. These will contain either a) HCTZ 12.5mg in both bottles; b) amiloride 5mg in both bottles; OR c) one bottle of each.~In Phase 2 (weeks13-24) patients will take 2 tablets from each of 2 bottles. These bottles will have the same contents as in Phase 1, except that the number of tablets will be twice as many.
Study: NCT01562431

Intervention type: OTHER
Group type: OTHER
Intervention: Feed-back
Description: Counselors will receive the results of the completed Signal-checklist completed by participants in the intervention group

Intervention type: OTHER
Group type: OTHER
Intervention: Feed-back
Description: Counselors will receive the results of the completed Signal-checklist completed by participants in the intervention group
Study: NCT01823315

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MTX 1
Description: MTX 0.4mg/(kg·d) intramuscularly (IM) on days 1-5

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MTX 1
Description: MTX 0.4mg/(kg·d) intramuscularly (IM) on days 1-5

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MTX 2
Description: MTX 100mg/m(2), IV, on day1 (after Act-d); MTX 200mg/m(2), IVgtt, on day1 (after MTX, 500ml NS, \>4h)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Act-d
Description: Act-d 0.6mg/m(2), IV, on day1,2
Study: NCT05334602

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Addition of dermal fat graft as protection over bone graft
Description: A barrier membrane
Study: NCT03553589

Intervention type: OTHER
Intervention: Blood sampling
Description: Blood sampling (10 mL) prior to standard care (e.g. surgery, medical treatment)

Intervention type: OTHER
Intervention: Blood sampling
Description: Blood sampling (10 mL) prior to standard care (e.g. surgery, medical treatment)
Study: NCT03165526

Intervention type: DEVICE
Intervention: AMPLATZER™ Post-infarct Muscular VSD Occluder
Description: The AMPLATZER™ PIVSD Occluder is intended for percutaneous transcatheter closure of post-myocardial infarct muscular VSDs in patients who are not satisfactory surgical candidates.

Intervention type: DEVICE
Intervention: AMPLATZER™ Post-infarct Muscular VSD Occluder
Description: The AMPLATZER™ PIVSD Occluder is intended for percutaneous transcatheter closure of post-myocardial infarct muscular VSDs in patients who are not satisfactory surgical candidates.
Study: NCT01878656

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane
Description: The investigators decrease to 1 minimal alveolar concentration(MAC) of anesthetic combination of sevoflurane and nitrous oxide, and maintain end-tidal concentration of anesthetic combination at 1 MAC until the end of surgery. At the end of surgery, sevoflurane and nitrous oxide are discontinued.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Desflurane
Description: The investigators decrease to 1 MAC of anesthetic combination of desflurane and nitrous oxide, and maintain end-tidal concentration of anesthetic combination at 1 MAC until the end of surgery. At the end of surgery, desflurane and nitrous oxide are discontinued.
Study: NCT04192617

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SM03
Description: SM03: 600 mg intravenous (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SM03
Description: SM03: 600 mg intravenous (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo: 600 mg intravenous (IV)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo: 600 mg intravenous (IV)
Study: NCT02507895

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MI-BCI
Description: Subjects will be seated comfortably in front of a computer screen. An EEG cap will be comfortably worn over the head of the subject to record EEG traces of any activated cortical areas. If subjects are able to activate the device and are agreeable to participate in the second phase of the study, they will be enrolled in a 4-week BCI-MI training program of 12 sessions. Subjects will be required to perform 160 trials of MI altogether with assigned rest periods (5 mins) every 40 trials. Each session will last approximate 45 minutes excluding set up time.
Study: NCT03185975

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: at-home test kit
Description: Transgender youth in the control arm will receive test kits, but will not receive any testing intervention. Once individual results are reported, participants will be contacted via phone or email by study staff with options for referrals to services. Participants will complete follow-up surveys at 3, 6, 9, and 12 months post-testing.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Motivational Interviewing and Certified Testing and Referral
Description: Transgender individuals randomized to the experimental group (MI/CTR) will receive HIV counseling and testing via an online, HIPPA-compliant videoconferencing service. The session will last less than one hour and focus on HIV testing, prevention strategies, and/or linkage to HIV care, depending on the individual's test results. Participants will complete follow up surveys at 3, 6, 9 and 12 months.
Study: NCT04192617

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: methotrexate: 7.5-20 mg/week oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: methotrexate: 7.5-20 mg/week oral

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Methotrexate
Description: methotrexate: 7.5-20 mg/week oral
Study: NCT05086081

Intervention type: DRUG
Intervention: Ticagrelor 90mg
Description: Any ticagrelor dispensing claim is used as the exposure group

Intervention type: DRUG
Intervention: Prasugrel 10mg
Description: Any prasugrel dispensing claim is used as the reference group
Study: NCT01098734

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: WBI-1001
Description: A 12-week study to assess the efficacy, safety and tolerability of topically applied WBI-1001 creams. First 6 weeks will be double-blinded, placebo-controlled and the following 6 weeks will be double-blinded, non-placebo- controlled. After 6 weeks patients in Groups 2 and 3 will continue double-blinded treatment for a further 6 weeks, but patients in Group 1 will enter a 6-week double-blinded phase with one of the two active creams (half treated with 0.5% and half with 1.0% WBI-1001 cream). All patients treated twice daily (BID).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: WBI-1001
Description: A 12-week study to assess the efficacy, safety and tolerability of topically applied WBI-1001 creams. First 6 weeks will be double-blinded, placebo-controlled and the following 6 weeks will be double-blinded, non-placebo- controlled. After 6 weeks patients in Groups 2 and 3 will continue double-blinded treatment for a further 6 weeks, but patients in Group 1 will enter a 6-week double-blinded phase with one of the two active creams (half treated with 0.5% and half with 1.0% WBI-1001 cream). All patients treated twice daily (BID).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: WBI-1001
Description: A 12-week study to assess the efficacy, safety and tolerability of topically applied WBI-1001 creams. First 6 weeks will be double-blinded, placebo-controlled and the following 6 weeks will be double-blinded, non-placebo- controlled. After 6 weeks patients in Groups 2 and 3 will continue double-blinded treatment for a further 6 weeks, but patients in Group 1 will enter a 6-week double-blinded phase with one of the two active creams (half treated with 0.5% and half with 1.0% WBI-1001 cream). All patients treated twice daily (BID).
Study: NCT02175407

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP1707
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP1707
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: itraconazole
Description: oral
Study: NCT04261933

Intervention type: DRUG
Intervention: semaglutide
Description: Patients will be treated with commercially available semaglutide in a prefilled pen injector (FlexTouch® variant) according to routine local clinical practice at the discretion of the treating physician. Other anti-hyperglycaemic treatments will be prescribed at the physician's discretion.
Study: NCT02236754

Intervention type: DRUG
Group type: OTHER
Intervention: 18 F-FP-DTBZ
Description: The drug, no carrier added \[18 F\]-FP-DTBZ, is formulated in 5% (v/v) ethanol in 0.9% sterile saline solution to produce \[18 F\]-FP-DTBZ for injection. Subjects will receive a single i.v. administration of no more than 7.6 millicuries (mCi) of \[18 F\]-FP-DTBZ for injection immediately prior to imaging. The specific activity at time of injection will less than 1.0 mCi/microgram and thus for a 7.6 mCi dose the maximal mass dose will be less than 10 microgram.

Intervention type: DRUG
Group type: OTHER
Intervention: 18 F-FP-DTBZ
Description: The drug, no carrier added \[18 F\]-FP-DTBZ, is formulated in 5% (v/v) ethanol in 0.9% sterile saline solution to produce \[18 F\]-FP-DTBZ for injection. Subjects will receive a single i.v. administration of no more than 7.6 millicuries (mCi) of \[18 F\]-FP-DTBZ for injection immediately prior to imaging. The specific activity at time of injection will less than 1.0 mCi/microgram and thus for a 7.6 mCi dose the maximal mass dose will be less than 10 microgram.

Intervention type: RADIATION
Group type: OTHER
Intervention: PET Scanning
Description: Individuals will be imaged continuously (i.e. dynamically) for 2 hours.

Intervention type: RADIATION
Group type: OTHER
Intervention: PET Scanning
Description: Individuals will be imaged continuously (i.e. dynamically) for 2 hours.
Study: NCT00493363

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Artesunate
Description: Artesunate 2 mg/kg/day for 7 days
Study: NCT01060163

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Saline served as placebo
Study: NCT04443881

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anakinra 149 MG/ML Prefilled Syringe [Kineret]
Description: Anakinra (100 mg/ 6 hours) i.v infusión during 15 days
Study: NCT00493363

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Artesunate + Mefloquine
Description: Artesunate 4mg/kg/day for 3 days plus mefloquine 15mg/kg on day 3 and 10mg/kg on day 4
Study: NCT01732393

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oral quercetin capsules
Description: 10 cases in case group and 10 cases in control group. Patients in the intervention group were administered two, 250 mg Quercetin capsules daily for 3 weeks. Patients in the placebo group received two placebo capsules containing lactose .Patients were examined every other day for evaluation of initiation and severity of oral mucositis.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00254254

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exenatide - Exenatide - Placebo
Description: Exenatide 2.5 mcg, single dose, followed by Exenatide 5 mcg, single dose, followed by placebo 0.02 mL, single dose. All are subcutaneous injections.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exenatide - Placebo - Exenatide
Description: Exenatide 2.5 mcg, single dose, followed by placebo 0.02 mL, single dose, followed by Exenatide 5 mcg, single dose. All are subcutaneous injections.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo - Exenatide - Exenatide
Description: Placebo 0.02 mL, single dose, followed by Exenatide 2.5 mcg, single dose, followed by Exenatide 5 mcg, single dose. All are subcutaneous injections.
Study: NCT02740933

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Demeclocycline
Study: NCT03812146

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PC-TIME
Description: PC-TIME consists of five, 30-minute sessions delivered over 8 weeks. Intervention will be delivered by a behavioral health provider and will consist of brief Prolonged Exposure for PTSD integrated with aspects of the Motivational Interviewing counseling approach.
Study: NCT01511900

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAT 1004
Description: Multiple dose oral administration once daily for 14 days of CAT 1004 at dose level 1-9 subjects will be treated with CAT-1004

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Multiple dose oral administration of placebo daily for 14 days-3 subjects will be treated with placebo per cohort

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Multiple dose oral administration of placebo daily for 14 days-3 subjects will be treated with placebo per cohort

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Multiple dose oral administration of placebo daily for 14 days-3 subjects will be treated with placebo per cohort

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Multiple dose oral administration of placebo daily for 14 days-3 subjects will be treated with placebo per cohort

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Multiple dose oral administration of placebo daily for 14 days-3 subjects will be treated with placebo per cohort

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAT 1004
Description: Multiple dose oral administration once daily for 14 days of CAT 1004 at dose level 2 -9 subjects will be treated with CAT-1004

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAT 1004
Description: Multiple dose oral administration BID for 14 days of CAT 1004 at dose level 3-9 subjects will be treated with CAT-1004

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAT 1004
Description: Multiple dose oral administration BID for 14 days of CAT 1004 at dose level 4-9 subjects will be treated with CAT-1004

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAT 1004
Description: Multiple dose oral administration daily for 14 days of CAT 1004 at dose level TBD-9 subjects will be treated with CAT-1004
Study: NCT02971345

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stent and Iodine-125 seed strand implantation
Description: The patent second-order branch of the intrahepatic portal vein was punctured with a 22-gauge Chiba needle under ultrasound guidance.Stent and Iodine-125 seed strand are implanted by two 0.035-inch,150-cm-long wire.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stent
Description: Bare stent should be placed through a 7-F, 23-cm-long sheath over the wire.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Iodine-125 seed
Description: The number of Iodine-125 seeds planned to be implanted was calculated by the following formula: N = length of obstructed main portal vein (mm)/4.5 + 4. These seeds were arranged linearly and sealed into a 4-F catheter continuously to construct a Iodine-125 seed strand.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epirubicin
Description: Epirubicin is a chemotherapy drug used in transarterial chemoembolization (TACE).Dosage: Epirubicin 30-60 mg per patient,depending on the situation of the patient.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epirubicin
Description: Epirubicin is a chemotherapy drug used in transarterial chemoembolization (TACE).Dosage: Epirubicin 30-60 mg per patient,depending on the situation of the patient.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ultra-fluid lipiodol
Description: Ultra-fluid lipiodol is a kind of embolization material used in TACE. Standard: 38% ultra-fluid lipiodol .

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ultra-fluid lipiodol
Description: Ultra-fluid lipiodol is a kind of embolization material used in TACE. Standard: 38% ultra-fluid lipiodol .

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gelatin sponge articles
Description: Gelatin sponge articles embolization material used in TACE. Standard: 350-560 um in diameter.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Gelatin sponge articles
Description: Gelatin sponge articles embolization material used in TACE. Standard: 350-560 um in diameter.
Study: NCT03628352

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tricaprilin
Description: Tricaprilin with flavoring agents added
Study: NCT00439751

Intervention type: DRUG
Group type: OTHER
Intervention: Goserelin Acetate
Description: Continuous goserelin, 12 week (10.8 mg) depot, will be used as ADT for both study arms. It is supplied as a sterile syringe for subcutaneous use.

Intervention type: DRUG
Group type: OTHER
Intervention: Goserelin Acetate
Description: Continuous goserelin, 12 week (10.8 mg) depot, will be used as ADT for both study arms. It is supplied as a sterile syringe for subcutaneous use.
Study: NCT05020054

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Tecartherapy Intervention
Description: therapeutic therapy with effective application, connected equipment

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: placebo tecartherapy
Description: tecartherapy with equipment turned off
Study: NCT01326702

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine Hydrochloride
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Veliparib
Description: Given PO
Study: NCT04601662

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Corticision
Description: A special instrument will be used to cut the cortex of the alveolar bone at different locations between the lower anterior teeth

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Non-accelerated Treatment
Description: The normal sequence of treatment steps will be followed in this group without using any kind of acceleration methods
Study: NCT02741362

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intravenous injection of Stromal Vascular Fraction Cells (SVF) containing ADSCs

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lipoaspiration
Study: NCT03533530

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Low-density ESI (LD ESI)
Description: Electrical source imaging using low density EEG

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: High-density ESI (HD ESI)
Description: Electrical source imaging using high density EEG

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: No electrical source imaging (ESI)
Description: For all patients: MRI, semiology, visual interpretation of EEG. When needed: PET, SPECT.
Study: NCT02833857

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etelcalcetide
Description: A single IV-bolus dose of 0.035 mg/kg etelcalcetide into the venous line of the dialysis circuit at the end of a hemodialysis session.
Study: NCT03272867

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: ProManna

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: ProManna
Study: NCT00361257

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Minocycline
Description: Tetracycline antibiotic, 100 mg taken orally every 12 hours

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Tetracycline)
Description: Tetracycline antibiotic placebo, orally every 12 hours
Study: NCT02856867

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nintedanib

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluorouracil

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fluorouracil

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leucovorin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Leucovorin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oxaliplatin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04079842

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: INVSENSOR00029
Description: Noninvasive pulse oximeter sensor
Study: NCT02626065

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: blood sampling
Description: Blood samples (44mL) will be taken before starting treatment with Nivolumab and at week 2, week 12, week 54 or at relapse (before week 54)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: blood sampling
Description: Blood samples (44mL) will be taken before starting treatment with Nivolumab and at week 2, week 12, week 54 or at relapse (before week 54)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: injection of Nivolumab every two weeks from day 0 and until relapse, toxicity motivating withdrawal or temporary suspension of treatment or up to 54 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: injection of Nivolumab every two weeks from day 0 and until relapse, toxicity motivating withdrawal or temporary suspension of treatment or up to 54 weeks.